{"protocolSection": {"identificationModule": {"nctId": "NCT02489981", "orgStudyIdInfo": {"id": "205.525"}, "organization": {"fullName": "Boehringer Ingelheim", "class": "INDUSTRY"}, "briefTitle": "Specific Use-result Surveillance of Spiriva Respimat in Asthmatics", "officialTitle": "Specific Use-result Surveillance of Spiriva Respimat in Asthmatics (Patients With Severe Persistent Asthma)"}, "statusModule": {"statusVerifiedDate": "2018-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-06-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2017-08-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-09-28", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-05-21", "studyFirstSubmitQcDate": "2015-07-01", "studyFirstPostDateStruct": {"date": "2015-07-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-08-30", "resultsFirstSubmitQcDate": "2018-08-30", "resultsFirstPostDateStruct": {"date": "2019-02-11", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-08-30", "lastUpdatePostDateStruct": {"date": "2019-02-11", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Boehringer Ingelheim", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The safety of Spiriva\u00ae 2.5 \u00b5g Respimat\u00ae 60 puffs (hereinafter referred to as Spiriva\u00ae Respimat\u00ae) in patients with severe persistent asthma under the real-world use was not confirmed in clinical trials."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 359, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Spiriva", "description": "Patients with severe persistent asthma", "interventionNames": ["Drug: Spiriva"]}], "interventions": [{"type": "DRUG", "name": "Spiriva", "description": "60 puffs", "armGroupLabels": ["Spiriva"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage of Patients With Suspected Adverse Drug Reactions (ADRs)", "description": "Percentage of patients with ADRs are presented. There was no primary outcome for effectiveness as the primary objective of the surveillance is the evaluation of safety.", "timeFrame": "Week 52"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Asthma Control Status at Week 52", "description": "The effectiveness was determined based on the change of asthma control status from baseline at Week 52 which is the secondary endpoint in the surveillance. The asthma control status was rated on a 3-point scale of well controlled, insufficiently controlled and poorly controlled based on asthma symptoms (in the daytime or at night), use of reliever and limitation of activities including exercise (based on \"Asthma prevention and management guideline\").\n\nWell-controlled=WC, Insufficiently-controlled=IC, Poorly-controlled=PC, Unknown=Unk, Missing=Miss, Baseline=BL, Week 52=W52", "timeFrame": "Baseline and Week 52"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n* Patients diagnosed with severe persistent bronchial asthma\n* Patient aged \\>= 15 years\n* Patients who are naive to Spiriva Respimat and receive Spiriva Respimat for the first time for treatment of bronchial asthma on top of at least ICS (Inhaled corticosteroids) treatment.\n\nExclusion criteria:\n\n* Patients who have a contraindication to Spiriva Respimat defined in the package insert for Spiriva Respimat\n* Patients who have been enrolled this study before.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "15 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"], "studyPopulation": "patients with severe asthma", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Boehringer Ingelheim", "affiliation": "Boehringer Ingelheim", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Hospital Fel\u00edcio Rocho", "city": "Belo Horizonte", "zip": "30110-060", "country": "Brazil", "geoPoint": {"lat": -19.92083, "lon": -43.93778}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "All patients were screened for eligibility to participate in the trial. Patients attended specialist sites to ensure that all patients met all inclusion/exclusion criteria. Patients were not to be entered to trial treatment if any one of the specific entry criteria were not met.", "recruitmentDetails": "The objective of this Post Marketing Surveillance (PMS) was to investigate the safety and effectiveness of Spiriva Respimat in patients with severe persistent asthma under real-world use. This is a regulatory required PMS to investigate the safety and effectiveness of Spiriva\u00ae 2.5 \u03bcg Respimat\u00ae 60 puffs in patients.", "groups": [{"id": "FG000", "title": "Spiriva\u00ae Respimat\u00ae", "description": "Patients were administered Tiotropium as two puffs 2.5 microgram (\u03bcg) (5 \u03bcg total dose) via the Respimat inhaler once daily"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "comment": "Started patients in the safety set", "achievements": [{"groupId": "FG000", "numSubjects": "340"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "213"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "127"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "21"}]}, {"type": "Insufficient effectiveness", "reasons": [{"groupId": "FG000", "numSubjects": "16"}]}, {"type": "Improved", "reasons": [{"groupId": "FG000", "numSubjects": "31"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "31"}]}, {"type": "Other than listed", "reasons": [{"groupId": "FG000", "numSubjects": "28"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Safety set: This patient set includes all patients who were documented to have taken at least one dose of Spiriva Respimat except for patients who had no observation documented after entry, made invalid registration or were not under the appropriate site contact.", "groups": [{"id": "BG000", "title": "Spiriva\u00ae Respimat\u00ae", "description": "Patients were administered Tiotropium as two puffs 2.5 microgram (\u03bcg) (5 \u03bcg total dose) via the Respimat inhaler once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "340"}]}], "measures": [{"title": "Age, Continuous", "description": "Age at the time of signing informed consent form is presented.", "populationDescription": "SafetySet", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "340"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "60.5", "spread": "15.0"}]}]}]}, {"title": "Sex: Female, Male", "description": "Number of subjects is categorized as Male or Female.", "populationDescription": "Safety Set", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "340"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "183"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "157"}]}]}]}, {"title": "Race and Ethnicity Not Collected", "populationDescription": "Race and Ethnicity were not collected from any participant.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage of Patients With Suspected Adverse Drug Reactions (ADRs)", "description": "Percentage of patients with ADRs are presented. There was no primary outcome for effectiveness as the primary objective of the surveillance is the evaluation of safety.", "populationDescription": "Safety set: This patient set includes all patients who were documented to have taken at least one dose of Spiriva Respimat except for patients who had no observation documented after entry, made invalid registration or were not under the appropriate site contact.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 52", "groups": [{"id": "OG000", "title": "Spiriva\u00ae Respimat\u00ae", "description": "Patients were administered Tiotropium as two puffs 2.5 microgram (\u03bcg) (5 \u03bcg total dose) via the Respimat inhaler once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "340"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.59"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Control Status at Week 52", "description": "The effectiveness was determined based on the change of asthma control status from baseline at Week 52 which is the secondary endpoint in the surveillance. The asthma control status was rated on a 3-point scale of well controlled, insufficiently controlled and poorly controlled based on asthma symptoms (in the daytime or at night), use of reliever and limitation of activities including exercise (based on \"Asthma prevention and management guideline\").\n\nWell-controlled=WC, Insufficiently-controlled=IC, Poorly-controlled=PC, Unknown=Unk, Missing=Miss, Baseline=BL, Week 52=W52", "populationDescription": "Efficacy set: This patient set is a subset of the safety set that includes all patients in the safety set who have baseline and at least one available on-treatment asthma control status, Peak Expiratory Flow Rate (PEFR), Forced Expiratory Volume in one second (FEV1), Forced Vital Capacity (FVC) or Asthma Control Questionnaire (ACQ) 6 score.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Spiriva\u00ae Respimat\u00ae", "description": "Patients were administered Tiotropium as two puffs 2.5 microgram (\u03bcg) (5 \u03bcg total dose) via the Respimat inhaler once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "248"}]}], "classes": [{"title": "WC_BL & WC_52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "66.67"}]}]}, {"title": "IC_BL & WC_52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "117"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "58.12"}]}]}, {"title": "PC_BL & WC_52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "35.14"}]}]}, {"title": "Unk_BL & WC_52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "50.00"}]}]}, {"title": "Miss_BL & WC_52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00"}]}]}, {"title": "WC_BL & IC_52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00"}]}]}, {"title": "IC_BL & IC_52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "117"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "17.95"}]}]}, {"title": "PC_BL & IC_52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "22.52"}]}]}, {"title": "Unk_BL & IC_52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "25.00"}]}]}, {"title": "Miss_BL & IC_52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "25.00"}]}]}, {"title": "WC_BL & PC_52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00"}]}]}, {"title": "IC_BL & PC_52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "117"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.27"}]}]}, {"title": "PC_BL & PC_52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "17.12"}]}]}, {"title": "Unk_BL & PC_52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00"}]}]}, {"title": "Miss_BL & PC_52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00"}]}]}, {"title": "WC_BL & Unk_52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00"}]}]}, {"title": "IC_BL & Unk_52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "117"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.56"}]}]}, {"title": "PC_BL & Unk_52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.90"}]}]}, {"title": "Unk_BL & Unk_52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "25.00"}]}]}, {"title": "Miss_BL & Unk_52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00"}]}]}, {"title": "WC_BL & Miss_52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "33.33"}]}]}, {"title": "IC_BL & Miss_52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "117"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "17.09"}]}]}, {"title": "PC_BL & Miss_52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "24.32"}]}]}, {"title": "Unk_BL & Miss_52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00"}]}]}, {"title": "Miss_BL & Miss_52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "75.00"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From first drug administration until 30 days after last drug administration.", "description": "The safety set (The safety set includes all patients registered in the study and received the treatment) was used for adverse event reporting. A total of 359 patients were registered and Case Report Form (CRFs) were collected from 352 patients. The safety set includes 340 patients, excluding 12 patients who had no visit after registration.", "eventGroups": [{"id": "EG000", "title": "Spiriva\u00ae Respimat\u00ae", "description": "Patients were administered Tiotropium as two puffs 2.5 microgram (\u03bcg) (5 \u03bcg total dose) via the Respimat inhaler once daily", "deathsNumAffected": 1, "deathsNumAtRisk": 340, "seriousNumAffected": 10, "seriousNumAtRisk": 340, "otherNumAffected": 0, "otherNumAtRisk": 340}], "seriousEvents": [{"term": "Anaphylactic reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 340}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 340}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 340}]}, {"term": "Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 340}]}, {"term": "Peritonsillar abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 340}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 340}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 340}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 340}]}, {"term": "Idiopathic pulmonary fibrosis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 340}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 340}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Patients were not randomized and there are no within-study data. Patients in the study may differ from the overall asthma-treated population, or from treated patients who did not choose to participate in the study."}, "certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Boehringer Ingelheim, Call Centre", "organization": "Boehringer Ingelheim", "email": "clintriage.rdg@boehringer-ingelheim.com", "phone": "1-800-243-0127"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2017-10-01", "uploadDate": "2018-08-30T06:06", "filename": "SAP_000.pdf", "size": 366882}, {"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2015-04-22", "uploadDate": "2018-08-30T06:06", "filename": "Prot_001.pdf", "size": 551986}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Germany", "Japan"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069447", "term": "Tiotropium Bromide"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000010276", "term": "Parasympatholytics"}, {"id": "D000018680", "term": "Cholinergic Antagonists"}, {"id": "D000018678", "term": "Cholinergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M416", "name": "Tiotropium Bromide", "asFound": "Liver Cancer", "relevance": "HIGH"}, {"id": "M5241", "name": "Bromides", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M13189", "name": "Parasympatholytics", "relevance": "LOW"}, {"id": "M20760", "name": "Cholinergic Antagonists", "relevance": "LOW"}, {"id": "M20758", "name": "Cholinergic Agents", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AntiConv", "name": "Anticonvulsants"}]}}, "hasResults": true}